|
WASHINGTON (AP) - Dermatologists are renewing their concerns that efforts to prevent pregnant women from using a drug that can cause birth defects may also keep the drug from patients who need it for severe acne.
The iPledge program to register women of childbearing age who use the drug Accutane and its generic versions — requiring them to have pregnancy tests before getting a prescription — is scheduled to take effect March 1.
The American Academy of Dermatology had urged the Food and Drug Administration to postpone the start of iPledge, but said Tuesday the FDA had advised it that the program will begin as planned.
|